Vergelijking

Buserelin vs. Linaclotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

57982-77-1

851199-59-2

Molecuulmassa

1239.42 g/mol

1526.74 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Buserelin	Linaclotid
Duitsland	Op recept	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Buserelin

Volledige vermelding →

Linaclotid

Volledige vermelding →

Frequently asked questions

What is the difference between Buserelin and Linaclotid?: Buserelin is classified as "Onderzoek (overig)", while Linaclotid is classified as "Onderzoek (overig)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Linaclotid?: The highest available evidence level is "Humane RCT" for Buserelin and "Humane RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Linaclotid in Germany and the United States?: Duitsland: Buserelin — Op recept, Linaclotid — Op recept. Verenigde Staten: Buserelin — Niet goedgekeurd, Linaclotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Linaclotid

Duitsland

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Buserelin and Linaclotid?

Buserelin is classified as "Onderzoek (overig)", while Linaclotid is classified as "Onderzoek (overig)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Linaclotid?

The highest available evidence level is "Humane RCT" for Buserelin and "Humane RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Linaclotid in Germany and the United States?

Duitsland: Buserelin — Op recept, Linaclotid — Op recept. Verenigde Staten: Buserelin — Niet goedgekeurd, Linaclotid — Op recept. These are factual summaries with source and review date on the individual pages.